Ritonavir oral tablet is a pharmacokinetic booster of multiple oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid (Nirmatrelvir 300 mg tablet + ritonavir 100 mg tablet co-administration package)
Its technology-centric solutions enable hospitals to enhance operational efficiency and enable faster clinical decision making
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
The award recognizes and supports promising women scientists
First and only once-weekly patch for convenient, well-tolerated delivery of most used drug for the treatment of Alzheimer's-related dementia
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Tislelizumab is now approved for seven indications in China
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
As the world celebrates World Glaucoma Week (March 7-13th), Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals, an authority on eye diseases spoke to Thomas C Thottathil, Editor, indianpharmapost.com, on the seriousness of Glaucoma
A total of 21 applicants have been approved for 49 products, with the potential to utilize an incentive amount of Rs. 2541 crore
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
